Published in final edited form as:

Fertil Steril. 2014 May ; 101(5): 1308–1314. doi:10.1016/j.fertnstert.2014.01.050.

A NOVEL “DELAYED START” PROTOCOL WITH GNRH ANTAGONIST IMPROVES OUTCOMES IN POOR RESPONDERS

Hakan Cakmak, M.D., Nam D. Tran, M.D. Ph.D., A. Musa Zamah, M.D. Ph.D., Marcelle I. Cedars, M.D., and Mitchell P. Rosen, M.D.

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California

Abstract

Objective—To investigate whether delaying the start of ovarian stimulation with GnRH antagonist improves ovarian response in poor responders.

Design—Retrospective study

Setting—Academic medical center

Patients—Thirty patients, who responded poorly and did not get pregnant with conventional estrogen priming antagonist IVF protocol.

Intervention(s)—Delayed start antagonist protocol (estrogen priming followed by early follicular phase GnRH antagonist treatment for 7 days prior to ovarian stimulation)

Main Outcome Measure(s)—Number of dominant follicles and mature oocytes retrieved, mature oocyte yield and fertilization rate.

Results—The number of patients who met the criteria to proceed to oocyte retrieval was significantly higher in delayed start protocol [21/30 (70%)] compared to patient’s previous conventional estrogen priming antagonist cycle [11/30 (36.7%)]. The number of dominant follicles was significantly higher in delayed start (4.2 ± 2.7) compared with conventional protocol (2.4 ± 1.3). In patients, who had oocyte retrieval after both protocols ($n=9$), the delayed start resulted in shorter ovarian stimulation (9.4 ± 1.4 vs. 11.1 ± 2.0 days), higher number of mature oocytes retrieved (4.9 ± 2.0 vs. 2.2 ± 1.1) and trend toward increased fertilization rates with ICSI ($86 \pm 17\%$ vs. $69 \pm 21\%$) compared to conventional protocol. After delayed start, the average number of embryos transferred was 2.8 ± 1.4 with implantation rate of 9.8% and clinical pregnancy rate of 23.8%.

Conclusions—The delayed start protocol improves ovarian response in poor responders, by promoting and synchronizing follicle development without impairing oocyte developmental competence.

Keywords

Delayed start; poor responder; controlled ovarian stimulation

INTRODUCTION

The goal of controlled ovarian stimulation (COS) in *in vitro* fertilization cycles is to recruit multiple follicles in an effort to compensate for the inefficiencies of embryo culture systems, and to increase the chance of creating euploid embryos and subsequent viable pregnancies (1). The prevalence of poor responders varies between 5.6 and 35.1% depending on the definition of poor response (2, 3). Regardless of the definition, a poor response to COS potentially results in high cancellation rates, a reduced number of oocytes retrieved, a decreased number of embryos available for transfer, and lower pregnancy rate compared with normal responders (3-5). Treatment of this common condition still remains a major challenge in assisted reproduction technology. Although many protocols have been proposed to increase ovarian response, there is presently insufficient evidence to support the routine use of any particular intervention either for pituitary down regulation, or ovarian stimulation or adjuvant therapy in the management of poor responders (6).

Various factors, including decreased ovarian reserve, have been associated with a poor response. However, alterations in intraovarian factors or gonadotropin receptor regulation could also contribute to suboptimal response (7, 8). Additionally, poor responses may partly result from a shortened follicular phase with limited ability to recruit a sizable cohort, or differential sensitivity of early antral follicles to FSH (9, 10).

The mechanisms underlying the heterogeneity of antral follicle responsiveness to gonadotropins during the early follicular phase remain unclear. A possible explanation for this phenomenon involves follicles being at different developmental stages with various FSH receptor levels due to recruitment of these follicles at different time points. Another major reason for the variable response to COS is interference due to the actions of endogenous gonadotropins. During the last days of the menstrual cycle, paralleling the breakdown of the corpus luteum, FSH concentration increases progressively to preserve antral follicles from atresia and ensure their subsequent growth (11). Depending on their inherent sensitivity to FSH, it is possible that some antral follicles are able to respond to the lower amounts of FSH than the others, and therefore to start their development during the late luteal phase and accentuate size discrepancies observed during the first days of the subsequent cycle leading to asynchronous growth with COS (12).

COS protocols for poor responders are designed to minimize early follicle selection in the luteal phase and optimize the follicular hormonal milieu and antral follicle responsiveness. One of the reasons behind using GnRH agonist or birth control pills in the late luteal phase is to suppress FSH rise and subsequent premature dominant follicle selection. However, for poor responders, down regulation protocol with GnRH agonist or birth control pills before antagonist protocol may cause over-suppression on ovarian function leading to low oocyte yield (13). As a result, incorporating estradiol pretreatment to the GnRH antagonist protocol gained attention to lower endogenous luteal FSH secretion without suppressing the ovarian

response. In previous studies, estradiol pretreatment was shown to improve follicle synchronization, and eventually resulted in more coordinated follicular development, leading to the recovery of more mature oocytes (14, 15). However, substantial number of patients still suffers from asynchronous follicle growth with this protocol, likely due higher early follicular phase FSH levels compared to down regulated protocols (16, 17).

In this study, we hypothesize that by delaying start of COS with GnRH antagonist pre-treatment for 7 days after estrogen priming, there will be further suppression of endogenous FSH during the early follicular phase resulting in more FSH responsive follicles, thus improving synchronous follicular development. To test this hypothesis, we compared the COS outcomes of delayed start antagonist protocol with the same poor responder patient's previous failed conventional estrogen priming antagonist cycle.

MATERIALS & METHODS

Study Population

This study received Institutional Board Review approval by the Committee for Human Research at the University of California, San Francisco (UCSF). The patients selected for inclusion were identified after review of all estrogen-priming GnRH antagonist IVF cycles performed at UCSF Center for Reproductive Health between June 2011 and April 2013. The patients, who met the Bologna poor responder criteria (18) and had an unsuccessful estrogen-priming GnRH antagonist IVF cycle (conventional) followed by a delayed start protocol, were included to the study for analysis. For patients with more than one such IVF cycles, only the first delayed start antagonist protocol and the last conventional cycle, preceding the delayed start protocol, were included for analysis to avoid repeated-measures bias.

Ovarian Stimulation Protocols

Prior to both conventional and delayed start protocols, all patients received estrogen priming (estradiol patch or tablet) starting a week after LH surge until menses. Baseline ultrasounds on cycle day 2 and after the completion of GnRH antagonist pre-treatment in delayed start protocol were performed to document absence of ovarian cyst or lead follicle >10 mm. In conventional protocol (standard antagonist protocol), ovarian stimulation with gonadotropins was started on cycle day 2 of menstrual cycle. In delayed start protocol, ovarian stimulation was started after 7 days of GnRH antagonist pretreatment (0.25 mg Ganirelix acetate, Organon) (Figure 1). In both protocols, 300 IU of FSH (Follistim, Merck or Gonal-F, EMD-Serono) and 150 IU of hMG (Menopur, Ferring) were used for ovarian stimulation. The patients used the same FSH preparation (Follistim, Merck or Gonal-F, EMD-Serono) in both conventional and delayed start protocols. The gonadotropin doses were maintained fixed throughout the whole stimulation period. GnRH antagonist (0.25 mg Ganirelix acetate, Organon) was added to prevent premature ovulation, when the lead follicle measured 12 mm, and was continued until the hCG trigger. Final oocyte maturation was triggered with hCG 10000 IU (Pregnyl; Schering Plough) when the largest two follicles attained a mean diameter of 18 mm with general cohort of follicles larger than 13 mm. Patients were allowed to proceed to oocyte retrieval if 3 or more follicles were in

the dominant range (>13mm in diameter). In case of less than 3 dominant follicles, the cycle was canceled and intrauterine insemination was performed. If there were three or more dominant follicles, oocyte retrieval was performed under transvaginal-ultrasound guidance 36 hours after hCG administration. After stripping the cumulus cells, intracytoplasmic sperm injection (ICSI) was performed with ejaculated sperm to mature (MII) oocytes in all cycles. None of the male partners had any history of infertility. ICSI was performed in all cases to prevent infrequent cases of fertilization failures with conventional IVF. All the embryos were transferred either post fertilization day 2 or 3 due to limited number of embryos.

Outcome Measures

The main outcome measure was the number of mature (metaphase II) oocytes collected after conventional vs. delayed start ovarian stimulation protocol. Secondary outcome measures included the number of dominant follicles (≥ 13 mm) on the day of hCG trigger, total number of oocytes retrieved, oocyte maturity rate (MII oocyte number/total oocyte number), oocyte yield (total number of oocytes retrieved/AFC), mature oocyte yield (number of mature oocytes retrieved/AFC), total dosage of gonadotropins (recombinant FSH and/or highly purified hMG) needed, number of days needed for ovarian stimulation, and fertilization rate (percentage of 2PN stage zygotes approximately 16 h after ICSI treatment). Since the conventional start cycle did not result in pregnancy by design, we were unable to compare pregnancy outcomes. However, for descriptive purposes the implantation rate was defined by the number of gestational sacs seen by transvaginal ultrasound divided by the number of embryos transferred. Clinical pregnancy rate was defined as presence of fetal heart motion by transvaginal ultrasound per embryo transfer.

Serum Assays

Serum estradiol assay was calibrated to known standards and validated by serial dilution. Estradiol was quantified in batch and duplicate, and was measured with commercially available automated chemiluminescent immunoassays on a DPC-Immulite 1000 (Diagnostic Products, Los Angeles, CA). Each test was run with 3 controls of low, medium, and high concentrations. Dilutions were performed before measurements of estradiol (1:1000) depending on the calibration range. The intra-assay coefficient of variation for estradiol was 11.9%. High and low results were repeated with appropriate dilution.

Statistical Analysis

The statistical analyses for parametric data were performed by using paired t-test. Non-parametric data were analyzed by use of McNemar's Test with Yates correction for continuity. Stata 12.1 software (StataCorp, College Station, TX) was used for analysis. Statistical significance was defined as $p < 0.05$.

RESULTS

Baseline characteristics of the patients included to the study are presented in Table 1. All the study patients had an unsuccessful estrogen-priming GnRH antagonist IVF cycle (conventional) followed by a delayed start protocol. The median time period between the two COS cycles was 4 months (range: 2-12 months). The number of patients, who met the

criteria to proceed to oocyte retrieval (three or more follicles ≥ 13 mm in diameter) were significantly higher in delayed start protocol [21/30 (70%)], compared to patient's previous conventional estrogen priming antagonist cycle [11/30 (36.7%)] ($p=0.016$) (Figure 2). Twelve patients, who have failed COS with previous conventional protocol due to poor response and had rescue intrauterine insemination, have met the criteria to proceed to oocyte retrieval with subsequent delayed start protocol. In contrast, only two patients met the criteria for oocyte retrieval after conventional antagonist cycle, but not with delayed start protocol.

The number of dominant follicles (≥ 13 mm) was significantly higher in delayed start COS (4.2 ± 2.7 , mean $\pm$ SD) when compared with conventional protocol (2.4 ± 1.3) (between group difference 1.87, CI 95% 1.01-2.72) ($p<0.001$). Twenty-one patients had higher, 5 had the same, and 4 had lower number of dominant follicles in delayed start COS compared to conventional protocol. The patients, who had less dominant follicles with delayed start, had significantly lower AFC (3.25 ± 0.5) compared to the rest of the patients (6.5 ± 2.0) ($p=0.003$). Delaying ovarian stimulation with GnRH antagonist resulted in increased serum estradiol levels on ovarian stimulation day 6 (561 ± 286 vs. 212 ± 147 pg/ml), day 8 (903 ± 409 vs. 479 ± 280 pg/ml) and on the day of hCG trigger (1589 ± 488 vs. 1175 ± 466 pg/ml) compared to conventional estrogen priming antagonist protocol.

Because only 9 patients met the criteria to proceed to oocyte retrieval in both and conventional and delayed start protocols, the rest of comparative analysis was performed only in these 9 patients. In delayed start antagonist protocol, shorter ovarian stimulation duration (9.4 ± 1.4 vs. 11.1 ± 2.0 days), lower total gonadotropin dose (4250 ± 641 vs. 5000 ± 884 IU), higher number of total (6.6 ± 2.6 vs. 4.3 ± 1.8) and mature (MII) oocytes (4.9 ± 2.0 vs. 2.2 ± 1.1) retrieved, higher oocyte maturity rate (MII oocyte/total oocyte) and mature oocyte yield (MII oocyte/AFC ratio) with more day 2 or 3 viable embryos transferred (3.4 ± 1.6 vs. 1.6 ± 1.2) were observed compared to preceding conventional estrogen priming antagonist COS cycle (Table 2). Although not significant, there was a trend for higher fertilization rate in delayed start cycles (Table 2).

When only the delayed start COS cycles that resulted in oocyte retrieval ($n=21$) were evaluated, the following results were obtained: The length of ovarian stimulation was 8.7 ± 1.4 days and total dose gonadotropins used was 3696 ± 728 IU. On the day of hCG trigger, there were 5.5 ± 2.3 follicles ≥ 13 mm in diameter with serum estradiol level of 1430 ± 505 pg/ml. Average of 6.1 ± 2.8 oocytes were retrieved and 4.9 ± 2.2 of them showed nuclear maturity (MII). Oocyte maturity rate and mature oocyte yield were 0.82 ± 0.14 and 0.77 ± 0.31 , respectively. Fertilization rate was 0.82 ± 0.20 . While 15 patients had day 2 embryo transfers, 6 had day 3 embryo transfers. The average number of embryos transferred was 2.8 ± 1.4 . The implantation and clinical pregnancy rates were 9.8% and 23.8% (5/21), respectively.

DISCUSSION

In poor responders, an increase in the number of oocytes and embryos is a critical aspect of a successful cycle given the generally diminished oocyte quality in these patients (19). In

this study, we described a novel protocol incorporating estrogen treatment in the preceding luteal phase and an immediate and short pituitary shutdown with GnRH antagonist in early follicular phase, followed by COS. We demonstrated that pretreatment with GnRH antagonists for 7 consecutive days before the onset of ovarian stimulation resulted in more synchronous follicle growth, higher mature oocyte yield, and more embryos to transfer, compared with conventional estrogen priming GnRH antagonist protocol. The results also showed that a significant number of women, who have failed COS due to poor response, have met the criteria to proceed to oocyte retrieval with subsequent delayed start protocol.

To date, few studies have evaluated whether a delayed start to ovarian stimulation improves COS outcomes. A recent randomized controlled trial among “normal” responders showed that early follicular phase GnRH antagonist pretreatment for 3 days resulted in a trend toward a higher number of retrieved oocytes but failed to yield significantly higher pregnancy rates (20). In another clinical trial performed among women with normal ovarian reserve, 3-day GnRH antagonist pretreatment before COS in an antagonist protocol improved oocyte maturity and fertilization rates, but did not change the pregnancy rates (21). In poor responders, delaying the ovarian stimulation with an GnRH antagonist protocol was shown to improve number of oocytes retrieved and embryos transferred (22). In that proposed protocol, 8-day GnRH antagonist pretreatment was started on cycle day 5–8 and two doses of GnRH antagonist (cetorelix acetate 3 mg) four days apart with daily progestin was used to lengthen the oocyte recruitment interval (22). In our study, the length of GnRH antagonist pretreatment was similar (7-day course of daily Ganirelix 250 mcg). However, we initiated GnRH antagonist much earlier (on cycle day 2; before the dominant follicle was selected) after estrogen priming to suppress early follicular phase FSH rise.

In ovarian stimulation, follicles are required to grow coordinately in response to exogenous gonadotropins to accomplish simultaneous maturation. Marked follicular size discrepancies results in decreased odds of oocyte maturation and fertilization potential, which can limit the number of embryos created and the probability of conception (23). These follicular discrepancies may be more common in those with decreased ovarian reserve.

It has been postulated that suppression of endogenous FSH in early follicular phase results in improved follicular development (24). In a GnRH antagonist protocol, higher serum gonadotropin concentrations are found at the beginning of ovarian stimulation compared with a GnRH agonist down-regulation protocol (16, 17). As a result, the unsuppressed FSH level at the start of a GnRH antagonist cycle allows the initial growth of a few leading follicles before the addition of exogenous FSH. The GnRH antagonist protocol with estrogen, birth control pills and GnRH antagonist pretreatment in preceding luteal phase offers simple alternatives to achieve endogenous gonadotropin suppression during the early follicular phase (15, 25, 26). In addition, GnRH antagonist administration in early follicular phase, resulting in a delayed start also results in rapid and reversible suppression of FSH, which may contribute to the improvement in follicular development (21).

The heterogeneity in follicular growth may be due to differences in the follicular sensitivity to FSH within the cohort (12). There are two possible explanations of heterogeneous FSH responsiveness of the follicles in early follicular phase. Firstly, FSH rise in the late luteal

phase may cause premature dominant follicle selection, which can be partially prevented by estrogen priming in antagonist cycle. Recent studies indicate multiple waves of follicle recruitment within a single interovulatory period (27-29). Another explanation is that recruitment of the follicles at different time points may result in follicles at different developmental stages with various FSH receptor levels. We hypothesize that GnRH antagonist pretreatment in the early follicular phase before COS may temporarily halt the follicular growth by suppressing the endogenous FSH and may provide hormonal milieu for the follicles to express similar amount of FSH receptors and consequently respond to gonadotropins with synchronous growth.

The limitations of this study, as with most published trials of stimulation protocols for poor responders, are its retrospective nature and small sample size. Our best measure to judge the efficacy of the delayed start protocol was the historical control of the patients' prior estrogen priming antagonist cycle. Moreover, only the patients who failed in their estrogen priming antagonist protocol underwent delayed start protocol which results in selection bias. Nevertheless because the daily doses of gonadotropins were fixed for the entire stimulation period, the differences observed between the estrogen levels and the follicular development of the two protocols compared are not biased. In addition, estradiol levels were not considered in deciding on hCG trigger administration. As a result, duration of stimulation reflects only follicular development characteristics.

Because each patient had failed conventional estrogen priming antagonist cycle followed by delayed start antagonist protocol, it is possible that the initial poor response in conventional antagonist cycle was idiosyncratic and that the improved response on the study regimen was caused by a selection bias. While subsequent improvement in response with the same stimulation has been observed in individual basis, it was previously demonstrated that when patients repeated the same ovarian stimulation strategy in consecutive cycles, no significant differences in COS outcomes were noted between the two cycles, suggesting internal consistency in response from cycle to cycle (30, 31). Other data showed that a change in protocol for the second cycle may impact outcomes in a positive or negative way with respect to oocyte recovery and total number of mature oocytes/embryos (30, 32, 33). In our study, nine patients had more than one COS cycles before delayed start protocol that all resulted in similar poor response. Therefore, we believe that significant improvement in COS outcomes with delayed start protocol are not likely based solely upon an idiosyncratic poor response.

In summary, the use of the delayed start protocol appears to improve ovarian responsiveness during COS and may result in more uniform follicular development, more mature oocytes retrieved, transfer of higher numbers of embryos, and possibly improved pregnancy rates compared to previous estrogen priming antagonist cycle in poor responders. Although this treatment protocol is longer and the total cost is higher, it gives new hope to poor responder cases. Ultimately, however, prospective randomized controlled trials will be necessary to determine whether delayed start protocol is superior compared to the other protocols for poor responders.

REFERENCES

1. Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. *Endocr Rev.* 2006; 27:170–207. [PubMed: 16434510]
2. Biljan MM, Buckett WM, Dean N, Phillips SJ, Tan SL. The outcome of IVF-embryo transfer treatment in patients who develop three follicles or less. *Hum Reprod.* 2000; 15:2140–4. [PubMed: 11006187]
3. Hendriks DJ, te Velde ER, Looman CW, Bancsi LF, Broekmans FJ. Expected poor ovarian response in predicting cumulative pregnancy rates: a powerful tool. *Reprod Biomed Online.* 2008; 17:727–36. [PubMed: 18983760]
4. Saldeen P, Kallen K, Sundstrom P. The probability of successful IVF outcome after poor ovarian response. *Acta Obstet Gynecol Scand.* 2007; 86:457–61. [PubMed: 17486468]
5. Ulug U, Ben-Shlomo I, Turan E, Erden HF, Akman MA, Bahceci M. Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles. *Reprod Biomed Online.* 2003; 6:439–43. [PubMed: 12831590]
6. Pandian Z, McTavish AR, Aucott L, Hamilton MP, Bhattacharya S. Interventions for ‘poor responders’ to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF). *Cochrane Database Syst Rev.* 2010:CD004379. [PubMed: 20091563]
7. De Sutter P, Dhont M. Poor response after hormonal stimulation for in vitro fertilization is not related to ovarian aging. *Fertil Steril.* 2003; 79:1294–8. [PubMed: 12798873]
8. Oudendijk JF, Yarde F, Eijkemans MJ, Broekmans FJ, Broer SL. The poor responder in IVF: is the prognosis always poor? a systematic review. *Hum Reprod Update.* 2012; 18:1–11. [PubMed: 21987525]
9. Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. *Endocr Rev.* 1997; 18:71–106. [PubMed: 9034787]
10. Surrey ES, Schoolcraft WB. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. *Fertil Steril.* 2000; 73:667–76. [PubMed: 10731523]
11. Chun SY, Eisenhauer KM, Minami S, Billig H, Perlas E, Hsueh AJ. Hormonal regulation of apoptosis in early antral follicles: follicle-stimulating hormone as a major survival factor. *Endocrinology.* 1996; 137:1447–56. [PubMed: 8625923]
12. Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR. Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. *J Clin Endocrinol Metab.* 1996; 81:1038–45. [PubMed: 8772573]
13. Schachter M, Friedler S, Raziel A, Strassburger D, Bern O, Ron-el R. Improvement of IVF outcome in poor responders by discontinuation of GnRH analogue during the gonadotropin stimulation phase--a function of improved embryo quality. *J Assist Reprod Genet.* 2001; 18:197–204. [PubMed: 11432110]
14. Fanchin R, Cunha-Filho JS, Schonauer LM, Kadoch IJ, Cohen-Bacri P, Frydman R. Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation regimens. *Fertil Steril.* 2003; 79:316–21. [PubMed: 12568840]
15. Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R. Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. *Hum Reprod.* 2003; 18:2698–703. [PubMed: 14645194]
16. Albano C, Felberbaum RE, Smits J, Riethmuller-Winzen H, Engel J, Diedrich K, et al. European Cetorelix Study Group. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetorelix and the LHRH-agonist buserelin. *Hum Reprod.* 2000; 15:526–31. [PubMed: 10686191]
17. Borm G, Mannaerts B, The European Orgalutran Study Group. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. *Hum Reprod.* 2000; 15:1490–8. [PubMed: 10875855]

18. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. *Hum Reprod.* 2011; 26:1616–24. [PubMed: 21505041]
19. Kligman I, Rosenwaks Z. Differentiating clinical profiles: predicting good responders, poor responders, and hyperresponders. *Fertil Steril.* 2001; 76:1185–90. [PubMed: 11730748]
20. Blockeel C, Riva A, De Vos M, Haentjens P, Devroey P. Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm injection treatment cycle: impact on ovarian stimulation. A pilot study. *Fertil Steril.* 2011; 95:1714–9. e1–2. [PubMed: 21300334]
21. Younis JS, Soltsman S, Izhaki I, Radin O, Bar-Ami S, Ben-Ami M. Early and short follicular gonadotropin-releasing hormone antagonist supplementation improves the meiotic status and competence of retrieved oocytes in in vitro fertilization-embryo transfer cycles. *Fertil Steril.* 2010; 94:1350–5. [PubMed: 19800061]
22. Frankfurter D, Dayal M, Dubey A, Peak D, Gindoff P. Novel follicular-phase gonadotropin-releasing hormone antagonist stimulation protocol for in vitro fertilization in the poor responder. *Fertil Steril.* 2007; 88:1442–5. [PubMed: 17481626]
23. Rosen MP, Shen S, Dobson AT, Rinaudo PF, McCulloch CE, Cedars MI. A quantitative assessment of follicle size on oocyte developmental competence. *Fertil Steril.* 2008; 90:684–90. [PubMed: 18249377]
24. Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? *Hum Reprod.* 2007; 22:2805–13. [PubMed: 17872909]
25. Fanchin R, Castelo Branco A, Kadoch IJ, Hosny G, Bagirova M, Frydman R. Premenstrual administration of gonadotropin-releasing hormone antagonist coordinates early antral follicle sizes and sets up the basis for an innovative concept of controlled ovarian hyperstimulation. *Fertil Steril.* 2004; 81:1554–9. [PubMed: 15193476]
26. Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study. *Hum Reprod.* 2004; 19:1993–2000. [PubMed: 15284212]
27. Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human menstrual cycle: a review. *Hum Reprod Update.* 2012; 18:73–91. [PubMed: 22068695]
28. Bentov Y, Esfandiari N, Gokturk A, Burstein E, Fainaru O, Casper RF. An ongoing pregnancy from two waves of follicles developing during a long follicular phase of the same cycle. *Fertil Steril.* 2010; 94:350, e8–11. [PubMed: 20138269]
29. Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. *Fertil Steril.* 2013; 100:1673–80. [PubMed: 23987516]
30. Ezeh UI, Rosen MP, Shen S, Rinaudo PF, Dobson AT, Cedars MI. What predicts stimulation response? Impact of stimulation choice versus patient capacity. *Fertil Steril.* 2006; 86:S178. [PubMed: 17055817]
31. Hoveyda F, Engmann L, Steele J, Lopez Bernal A, Barlow DH. Ovarian response in three consecutive in vitro fertilization cycles. *Fertil Steril.* 2002; 77:706–10. [PubMed: 11937120]
32. Lai Q, Zhang H, Zhu G, Li Y, Jin L, He L, et al. Comparison of the GnRH agonist and antagonist protocol on the same patients in assisted reproduction during controlled ovarian stimulation cycles. *Int J Clin Exp Pathol.* 2013; 6:1903–10. [PubMed: 24040457]
33. Takahashi K, Mukaida T, Tomiyama T, Goto T, Oka C. GnRH antagonist improved blastocyst quality and pregnancy outcome after multiple failures of IVF/ICSI-ET with a GnRH agonist protocol. *J Assist Reprod Genet.* 2004; 21:317–22. [PubMed: 15587144]

Figure 1.
Outline of conventional estrogen priming and delayed start antagonist COS protocols.

Figure 2.

Comparison of percent of cycles met the criteria to proceed to oocyte retrieval in conventional and delayed start COS cycles. * $p=0.016$.

Table 1

Demographics and baseline characteristics of patients (n=30) who underwent estrogen priming antagonist controlled ovarian stimulation cycle followed by delayed start protocol

Age (years)	41.5 (34-44)
Body Mass Index (kg/m²)	22.6 (18.9-29.0)
Ethnicity	
Caucasian	20 (66.7%)
Asian	10 (33.3%)
Previous Pregnancy	15 (50%)
Previous Live Birth	5 (16.7%)
Antral Follicle Count	6 (3-11)
Length of Infertility (months)	23.5 (8-60)
Previous IVF cycle	9 (30%)
Number of previous IVF cycles	1 (1-2)
Time between two COS cycles (months)	4 (2-12)

Values are median (range) or n (%). COS: Controlled ovarian stimulation.

Table 2
Comparison of characteristics and outcomes of conventional and delayed start COS cycles

	Conventional Start (n=9)	Delayed Start (n=9)	Between-group difference (95% confidence interval)	p value
Days of ovarian stimulation	11.1 ± 2.0	9.4 ± 1.4	- 1.7 (-3.1, -0.3)	0.024
Total dose of gonadotropins (IU)	5000 ± 884	4250 ± 641	-750 (-1374, -126)	0.024
Endometrial thickness (mm)	9.5 ± 2.2	10.9 ± 2.5	1.4 (-0.2, 3.1)	0.082
Follicles 13 mm	3.9 ± 1.3	6.7 ± 2.2	2.8 (1.3, 4.3)	0.002
Oocytes retrieved	4.3 ± 1.8	6.6 ± 2.6	2.3 (0.13, 4.3)	0.04
Mature oocytes (MII) retrieved	2.2 ± 1.1	4.9 ± 2.0	2.7 (1.1, 4.2)	0.004
MI I oocyte / total oocytes ratio	0.53 ± 0.20	0.73 ± 0.10	0.20 (0.01, 0.4)	0.041
Oocyte / AFC ratio	0.76 ± 0.36	1.13 ± 0.21	0.37 (0.06, 0.68)	0.024
Mature oocyte / AFC ratio	0.38 ± 0.19	0.86 ± 0.21	0.48 (0.24, 0.72)	0.003
Fertilization rate after ICSI (2PN/MI I)	0.69 ± 0.21	0.86 ± 0.17	0.17 (-0.10, 0.44)	0.17
Day of transfer				
Day 2	8 (100%) ^a	6 (67%)		
Day 3	0	3 (33%)		
Embryos Transferred	1.6 ± 1.2	3.4 ± 1.6	1.8 (0.5, 3.0)	0.013
Implantation Rate	0	6.5 %		
Clinical Pregnancy Rate	0	2 (22.2%)		

^a One patient did not have any viable oocyte at the time of retrieval